Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect

BMC Complementary and Alternative Medicine

Toshikazu Yoshikawa²  Yuji Naito²  Masahiro Yamamoto¹  Naoko Tsuchiya¹  Chinami Matsumoto¹  Tatsushi Omatsu²  Kazuo Ogawa¹ 

[1]TSUMURA Research Laboratories, TSUMURA & CO, 3586 Yoshiwara, Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan

[2]Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan

关键词: Albumin fragment;    SELDI TOF-MS;    Juzentaihoto;    Bone marrow suppression;    TS-1;   

Others  :  1232097
DOI  :  10.1186/1472-6882-12-118

 received in 2012-02-10, accepted in 2012-08-05,  发布年份 2012

【 摘 要 】

Background

TS-1 is an oral anticancer drug containing a 5-fluorouracil derivative (Tegafur) that is widely used in Japan for the treatment of cancer, especially gastrointestinal tumors. Frequently, however, TS-1 therapy has to be discontinued because of leukopenia. If it were possible to predict the development of bone marrow suppression before the white blood cell (WBC) count had actually decreased, treatment could be improved by strict dosage control and/or the prophylactic administration of hematopoietic drugs. Juzentaihoto (JTT), a traditional Japanese medicine (Kampo), has been reported to activate hematopoiesis and reduce the side effects associated with chemotherapy and radiotherapy. Here, we 1) evaluate the efficacy of JTT in alleviating myelosuppression induced by TS-1 therapy in mice, and 2) explore biomarkers that reflect both induction by TS-1 and alleviation by JTT of bone marrow suppression using a proteomics approach.

Methods

Ten mg/kg of TS-1 was administered to Balb/c mice with or without 1 g/kg of oral JTT for 3, 5 and 7 days. WBC count and ratio of CD34⁺ bone marrow cells (BMCs) were estimated by flow cytometry. Plasma samples were analyzed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI TOF-MS). A biomarker candidate from SELDI profiling was identified using a combination of cation exchange spin column purification, SDS-PAGE, enzymatic digestion and LC-MS/MS.

Results

After administration of TS-1, a significant decrease in WBC count and CD34⁺ BMC ratio were observed at days 5 and 3, respectively. JTT treatment improved WBC count on day 7 and CD34⁺ BMC ratio on days 5 and 7. SELDI analysis highlighted three protein peaks that had increased on day 3 after treatment with TS-1 but remained unchanged in mice co-treated with JTT. One of the three peaks, m/z 4223.1, was further investigated and identified as a specific C-terminal fragment of albumin.

Conclusion

This study indicates that bone marrow suppression by treatment with TS-1 in mice might be improved by coadministration of JTT. A C-terminal fragment of albumin was identified as a candidate biomarker for predicting TS-1-induced myelosuppression. However, the sensitivity and specificity of the biomarker candidate must be validated in future clinical studies.

【 授权许可】

   
2012 Ogawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7:548-557.
• [2]Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N, Fukushima M: Antitumor Activity of 1M Tegafur-0.4M 5-Chloro-2,4-dihydroxypyridine-1M potassium Oxonate (S-1) against Human Colon Carcinoma Orthotopically Implanted into Nude Rats. Cancer Res 1996, 56:2602-2606.
• [3]Shirasaka T: Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. J Clin Oncol 2009, 39:2-15.
• [4]Saiki I: A Kampo medicine “Juzen-taiho-to” –Prevention of malignant Progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull 2000, 23:677-688.
• [5]Hisha H, Yamada H, Sakurai MH, Kiyohara H, Li Y, Yu C, Takemoto N, Kawamura H, Yamaura K, Shinohara S, Komatsu Y, Aburada M, Ikehara S: Isolation and identification of hematopoietic stem cell-stimulating substances from Kampo (Japanese herbal) medicine, Juzen-taiho-to. Blood 1997, 90:1022-1030.
• [6]Sugiyama K, Ueda H, Ichio Y, Yokota M: Improvement of cisplatin toxicity and lethality by Juzen-taiho-to in mice. Biol Pharm Bull 1995, 18:53-58.
• [7]Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
• [8]Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW: Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003, 3:2310-2316.
• [9]Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002, 48:1835-1843.
• [10]Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE: Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003, 63:6971-6983.
• [11]Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Bush AI: Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet 2003, 361:1258-1265.
• [12]Tomosugi N: Discovery of disease biomarkers by ProteinChip system; clinical proteomics as noninvasive diagnostic tool. Rinsho Byori 2004, 52:973-979.
• [13]Shirasaka T, Shimamoto Y, Fukushima M: Inhibition of oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993, 53:4004-4009.
• [14]Shirasaka T, Yamamitsu S, Tsuji A, Taguchi T: Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 2000, 18:315-329.
• [15]Ogawa K, Kojima T, Matsumoto C, Kamegai S, Oyama T, Shibagaki Y, Muramoto H, Kawasaki T, Fujinaga H, Takahashi K, Hikiami H, Goto H, Kiga C, Koizumi K, Sakurai H, Shimada Y, Yamamoto M, Terasawa K, Takeda S, Saiki I: Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clin Biochem 2007, 40:1113-1121.
• [16]Matsumoto C, Kojima T, Ogawa K, Kamegai S, Oyama T, Shibagaki Y, Kawasaki T, Fujinaga H, Takahashi K, Hikiami H, Goto H, Kiga C, Koizumi K, Sakurai H, Muramoto H, Shimada Y, Yamamoto M, Terasawa K, Takeda S, Saiki I: A proteomic approach for the diagnosis of ‘Oketsu’ (blood stasis), a pathophysiologic concept of Japanese traditional (Kampo) medicine. Evid Based Complement Alternat Med 2008, 5:463-474.
• [17]Marcus R, Eric P, Gabriel KR: On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976, 63:655-660.
• [18]Kawamura H, Maruyama H, Takemoto N, Komatsu Y, Aburada M, Ikehara S, Hosoya E: Accelerating effect of Japanese Kampo medicine on Recovery of murine haematopoietic stem cells after administration of mitomycin C. Int J Immunotherapy 1989, 5:35-42.
• [19]Maruyama H, Takemoto N, Maruyama N, Komatsu Y, Kawamura H: Antitumour effect of juzentaiho-to, a Kampo medicime, combined with surgical excision for transplanted Meth-A fibrosarcoma. Int J Immunotherapy 1993, 9:117-125.
• [20]Ohnishi Y, Yasumizu R, Fan HX, Liu J, Takao-Liu F, Komatsu Y, Hosoya E, Good RA, Ikehara S: Effect of juzen-taiho-toh (TJ-48), a traditional oriental medicine, on hematopoietic recovery from radiation injury in mice. Exp Hematol 1990, 18:18-22.
• [21]Hoff PM: The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL™) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000, 18:331-342.
• [22]Nabeya K, Ri S: Effect of oriental medical herbs on the restoration of the human body before and after operation. Pro. Symp WAKAN-YAKU 1983, 16:201-206.
• [23]Terasawa K, Shimada Y, Kita T, Yamamoto T, Tosa H, Tanaka N, Saito Y, kanaki E, Goto S, Mizusima N, Fujioka M, Takase S, Seki H, Kimura I, Ogawa T, Nakamura S, Araki G, Maruyama I, Maruyama Y, Takaori S: Choto-san in the treatment of vascular dementia: a double-blind, placebo-controlled study. Phytomedicine 1997, 4:15-22.
• [24]Miyamoto T, Inoue H, Kitamura S, Yamamoto M, Yamakido M, Nagano H, Egashira Y, Nakashima M: Effect of TSUMURA Sho-seiryu-to (TJ-19) on bronchitis in a double-blind placebo-controlled Study. J Clin Ther Med 2001, 17:1189-1214.
• [25]Kiga C, Nakagawa T, Koizumi K, Sakurai H, Shibagaki Y, Ogawa K, Goto H, Saiki I: Expression patterns of plasma proteins in spontaneously diabetic rats after oral administration of a Kampo medicine, Hachimi-jio-gan, using SELDI ProteinChip platform. Biol Pharm Bull 2005, 28:1031-1037.
• [26]Grochow LB, Noe DA, Effinger DS, Donehower RC: A phase I trial of trimetrexate (NSC 352122) given every 3 week: clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol 1989, 24:314-320.
• [27]Kimura M, Morihata K, Ito D, Iwai M, Okada K, Usami E, Nakao T, Yoshimura T, Yasuda T: Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer. Gan To Kagaku Ryoho 2010, 37:829-834.
• [28]Mick R, Ratain MJ: Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 1991, 83:1560-1564.
• [29]Kaul S, Srinivas NR, Igwemezie LN, Barbhaiya RH: A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients. Semin Oncol 1996, 23(Suppl 13):15-22.
• [30]Arakawa A, Nishikawa H, Suzumori K, Kato N: Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer. Int J Clin Oncol 2001, 6:248-252.
• [31]Heissig B, Lund LR, Akiyama H, Ohki M, Morita Y, Rømer J, Nakauchi H, Okumura K, Ogawa H, Werb Z, Danø K, Hattori K: The plasminogen fibrinolytic pathway is required for hematopoietic regeneration. Cell Stem Cell 2007, 1:658-670.
• [32]Heissig B, Ohki M, Ishihara M, Tashiro Y, Nishida C, Gritli I, Rosenkvist J, Hattori K: Contribution of the fibrinolytic pathway to hematopoietic regeneration. J Cell Physiol 2009, 221:521-525.
• [33]Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ: Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009, 19:471-477.
• [34]Vento G, Tirone C, Lulli P, Capoluongo E, Ameglio F, Lozzi S, Cota F, Mosca F, Romagnoli C, Messana I, Castagnola M, Inzitari R: Bronchoalveolar lavage fluid peptidomics suggests a possible matrix metalloproteinase-3 role in bronchopulmonary dysplasia. Intensive Care Med 2009, 35:2115-2124.
• [35]Hellin JL, Bech-Serra JJ, Moctezuma EL, Chocron S, Santin S, Madrid A, Vilalta R, Canals F, Torra R, Meseguer A, Nieto JL: Very low-molecular-mass Fragments of Albumin in the plasma of patients with focal segmental glomerulosclerosis. Am J Kidney Dis 2009, 54:871-880.
• [36]Wong F: Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007, 4:43-51.
• [37]Nicholson JP, Wolmarans MR, Park GR: The role of albumin in critical illness. Br J Anaesth 2000, 85:599-610.
• [38]Avidan B: The use of albumin in all patients with decompensated cirrhosis is not justified. Isr Med Assoc J 2005, 7:118-120.
• [39]Rena NM, Wibawa ID: Albumin infusion in liver cirrhotic patients. Acta Med Indones 2010, 42:162-168.
• [40]Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A: Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006, 94:1898-1905.
• [41]Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, Santamaria C, Ache A, Duncan M, Powell MR, Ward BJ: Identification of novel diagnostic serum biomarkers for Chagas’ disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 2010, 48:1139-1149.